List of Small Molecule Pharmaceuticals Companies in Texas - 53

7 Hills Pharma is a clinical-stage immunotherapy company developing a platform of novel, oral small molecules for the treatment of cancer and prevention of infectious diseases. Our compounds are first-in-concept allosteric integrin activators that leverage a unique mechanism of action to stabilize the cell-cell interactions required to mount an effective immune response. Our lead clinical candidate, 7HP349, is the only reported systemically safe immune stimulant that can activate both cellular and humoral immunity.

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Actuate Therapeutics, Inc. is a private clinical stage biopharmaceutical company focused on the treatment of cancer and inflammatory diseases leading to fibrosis.

The statistics are overwhelming: more than 130 people a day die from opioid related drug overdoses. In 2020 in the US alone, 2.7 million people aged 12 or older had Opioid Use Disorder (OUD) and 4.2 million people entered a drug rehabilitation program. While treatment programs and rescue medications are critical, æther THERAPEUTICS is focusing our efforts upstream: preventing addiction and creating a more effective treatment of OUD. æther THERAPEUTICS' main candidate is Low Dose 6β-Naltrexol (ATX-001). Animal models indicate that ATX-001 may prevent opioid dependence while not blocking pain relief or causing withdrawal & other adverse effects. Our vision is a world where the devastating effects of opioid addiction are alleviated, leading to: • Safer opioid pain therapy without the fear of addiction, • Cessation of opioid addiction • Prevention of Neonatal Opioid Withdrawal Syndrome (NOWS) æther THERAPEUTICS is focused on our vision, driven by innovation, embraces lean operations and engaged with urgency.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

AROG Pharmaceuticals, Inc. was formed to expedite and streamline the transition of early stage molecules into areas of unmet therapeutic needs. We are committed to scientifically validated drug development in collaboration with like-minded investigators and institutions.

AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs. Our pipeline of drug candidates is based on a new platform technology that modulates macrophages in the innate immune system to restore balance while fighting both infection and inflammation. Stimulating these macrophages produces a rapid therapeutic response throughout the body as we have seen in our strong preclinical data. This is unlike any existing immunotherapies today - immunotherapies which in total have annual sales of $70B. Because the antimicrobial action of our compounds is through the activation of phagocytosis, the development of multidrug resistance is not anticipated. Our goal is to save and improve lives, reduce hospital costs, & provide an effective treatment to diseases like BPD, VAP, and ARDS with no adverse side effects that are seen with the current alternatives. Our lead candidate is Orphan Drug and Rare Pediatric Disease Designated by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. BPD is a rare pediatric lung disease in preterm babies caused by inflammation from supplemental oxygen required for survival in the NICU and is the second leading cause of death in preterm babies. An average of 112 preterm babies die per month in the US due to the lack of an effective therapy and survivors require ongoing care. AyuVis has 2 patents approved by the USPTO and more countries which include composition of matter of our compounds, methods of use, formulations, and more.

Cao Pharmaceuticals is an early clinical stage oncology drug development company with a rich and deep history. We are committed to develop highly effective drugs with low and manageable toxicity for various cancers. And within much shorter timeframes compared to traditional chemotherapy development. Cao Pharmaceuticals is currently conducting a Phase I trial with their lead drug. Phase II trials are scheduled for Q3 2017.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

As an AAHRPP-accredited IRB, Salus IRB is committed to upholding the highest standards in human research protection while providing concierge customer service and consultative expertise. Salus works with sponsors and investigators to add value by delivering IRB services in a convenient, reliable, and efficient manner. Salus IRB provides ethical review for all phases of research in a variety of therapeutic areas and study designs in the pharmaceutical, biotech and medical device industries, and for single- and multi-site trials. We also provide ethical review for behavioral and social sciences research including data collection, repository, surveys, outcomes, and registries. With multiple meetings weekly and industry-leading 21 CFR Part 11 compliant technologies, our turnaround time for review is 24-48 hours. Our online submission platform, SafeSync and virtual workspace, Globesync™, allow secure, 24/7 access to your complete IRB study file throughout the process.

Ceutical Laboratories provides services to the pharmaceutical, medical device, dietary supplement, veterinary, cosmetic, and food industries. Ceutical Labs provides formulation development, design development, project management, process development, analytical testing (chemistry, microbiology, and physical testing), consulting, training, regulatory submissions (IND, NDA , ANDA, 510K, PMA, etc.), regulatory compliance, ESG submissions, quality system implementation, validation support, FDA management, auditing, IT solutions, and marketing expertise. YOUR SUCCESS is our goal. Analytical testing equipment includes GC, GC/MS, HPLC, HPLC/MS, HPLC/MS/MS, ICP, AAS, XRF, Polarimeter, and much more. Our formation expertise includes Rx, solid dose, topicals, and parenterals. Our laboratory has over 50,000 square feet. Our training facility has over 10,000 square feet. We will meet and exceed your expectations. We seek to help our customers achieve regulatory compliance. Our customers who have fully implemented our quality systems have received very few to no observations. We are routinely inspected by US FDA and Health Canada. Our goal is to remain compliant. We are a third party sampling and testing laboratory for US FDA.

Chemi Nutra offers science-based nutritional ingredients that address a variety of nutrition and performance-related applications. Chemi S.p.A., the parent company of Chemi Nutra, is a 40+ year-old, privately held nutraceutical and pharmaceutical company, based in Milan, Italy, with several production facilities located in both Italy and Brazil. The combined expertise allows our companies to be engaged in the entire process of bringing a nutraceutical to market — innovation, development, manufacture, marketing, and sales. We offer valuable assistance in developing unique and profitable nutritional products utilizing our knowledge of science, creativity, and targeted marketing.

Clinical Trial Network offers quality medical attention to the Houston area, while gathering data to generate industry-leading clinical research to pharmaceutical, bio-technology sponsors, and leading Contract Research Organizations.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

Community Clinical Health is a community of mental health professionals dedicated to the compassionate and ethical conduct of clinical trials of investigational pharmaceuticals for person with mental illness.

CoRegen is leveraging its groundbreaking master gene regulator platform to develop a broad range of therapeutics capable of controlling numerous genes throughout the body, with lead indications in solid tumors.

Crown Aesthetics, the premier medical aesthetics company, is dedicated to helping leading plastic surgeons, dermatologists, and aesthetic physicians around the world grow their businesses. We do that by delivering dramatic results in rejuvenation and restoration. Our non-invasive innovations – SkinPen®, the first FDA-cleared microneedling device; the post-microneedling protocol Skinfuse® and the platelet-rich plasma system ProGen™ – act as "gateway" products that draw new consumers to practices. Based in Dallas, Texas, Crown Aesthetics sets industry standards for efficacy, safety, and innovation. As a result, our customers consistently deliver the best aesthetic care in the business. Learn more at CrownAesthetics.com.

Curtana Pharmaceuticals is a privately-held, preclinical-stage biopharmaceutical company developing first-in-class, small molecule therapeutics that are highly specific for cancer stem cells in the central nervous system (CNS) for the treatment of glioblastoma (GBM) and other brain cancers.

Deaton Engineering, Inc. (DEI) is a nationally established, full-service mechanical, electrical, software control engineering and integration company located in Georgetown, Texas. Established in 1991, DEI offers a wide variety of solutions and services to a broad range of industries with a focus on turnkey engineering and product development services for the life-sciences industries. Composed of a diverse group of Texas licensed Professional Engineers, engineers, designers, and technical staff, Deaton Engineering develops ideas or products from concept through implementation.

Detekt is a life sciences product design and engineering firm. Over the last 15 years, the team has worked alongside both private and public companies to launch products that fulfill each client’s vision and successfully go to market.

DPT Laboratories CDMO Services is a pharmaceutical contract development and manufacturing organization specializing in semi-solid and liquid dosage forms, with a legacy of excellence dating back 80 years.

Emtora Biosciences is a life science company developing a novel formulation of rapamycin, eRapa™, for use in preventing the onset and recurrence of cancer. A Phase 1b safety and dosing clinical trial is underway in early stage prostate cancer patients. A pilot efficacy study in Familial Adenomatous Polyposis (FAP) is planned for late 2019.

Erimos is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics to treat cancer and viral diseases. We are dedicated to harnessing our innovative technology to meaningfully improve the lives and health outcomes of patients.

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

FGH BioTech develops novel drugs for metabolic diseases and cancer.

ImmunoMet Therapeutics is a clinical stage biotech targeting cellular metabolism to develop novel anti-fibrotic and anti-tumor therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor that targets the Oxidative Phosphorylation (OXPHOS) pathway in mitochondria and decreases aberrant cell growth in fibrosis and select cancer cells. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good tolerability. In fibrosis, ImmunoMet is currently conducting a Phase 1 study in healthy volunteers and plan to progress into Phase 2 PoC study in IPF patients in 4Q2021. The company was founded in 2015, is a spin-off from HanAll Biopharma, a Korean midsized public company, and has raised $31 MM post-spin-off.

Impact Biomedical, Inc. is an emerging human healthcare company and is a wholly owned subsidiary of DSS, Inc.

We are committed to providing fluorescent indicators, assay kits, and expert services that generate meaningful results for cell biology research and pre-clinical drug discovery. As scientists, our vision is to create innovative tools for others just like us - with a primary focus on drug discovery for ion channels, ion transporters, and GPCRs. Our team has over 50 years of experience synthesizing fluorescent indicators and conducting cell-based research. So whether your discoveries are forged under the lens of a microscope, on a plate reader, or in a high-throughput environment, ION Biosciences’ has you covered.

We develop novel therapeutic and diagnostic agents directed at severe diseases. Our specialty is therapeutic radiopharmaceuticals. IsoTherapeutics has been acquired by Telix Pharmaceuticals.

KJ Scientific LLC is a certified Woman Owned Small Business (WOSB) and a Historically Underutilized Business (HUB) with a global reach. We were founded with a mission of ensuring human and environmental health through rigorous testing and analysis of chemicals and products introduced to the market. To uphold these high standards, we became the first biotech lab in the world to exclusively use innovative in vitro technology in our chemical testing products and services. This new method reduces expenses, decreases experimentation time and significantly cuts down on the number of animals required for testing - all while delivering reliable and sustainable chemical analysis. We have extensive experience testing and analyzing a wide range of chemicals and products. Our lab offers customized chemical metabolism studies for bioaccumulation potential. Our experts also welcome the request to analyze or consult on third-party studies. We provide world class products to those who conduct their own bioassays, as well, sourced from reliable rainbow trout strains. KJ Scientific has proven world-leading expertise in this field. We are one of seven laboratories that participated in the OECD Ring Trial which resulted in the development of test guidelines on determination of in vitro intrinsic clearance using cryopreserved rainbow trout hepatocytes and liver S9 subcellular fractions. The multi-year process established guidelines that all laboratories conducting in vitro experiments must follow. The scientists at KJ Scientific conduct all experiments and processes in the Spirit of Good Laboratory Practices (GLP) and adhere to the European Commission's REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) initiative. We understand that our work can identify potential risks to environmental health so we guarantee that our products and services are delivered with the highest levels of integrity, responsibility, accuracy and dependability.

L7 Informatics provides a unified data and process platform (L7|ESP™) to streamline and optimize manufacturing, laboratory, and business processes across life sciences and healthcare value chains. The L7 Informatics' Unified Platform L7|ESP, with its Workflow Orchestration and Data Contextualization, meets the organizational needs of any life science organization digitalizing their data and laboratory processes, of which the result is maximized total ROI (return of investment), increased utilization and efficiency, and decreased overall cost. L7|ESP captures routine information in smaller labs, while also driving sophisticated wet and dry laboratory processes across an enterprise organization which requires data and analytics strategies that support LotF (lab of the future). The L7|ESP platform integrates all common data information management systems, including LIMS, Notebooks, and MES, but also other resources such as instrument connectors, sample registration, location, receipt accessioning, logistics, scheduling, inventory, environment monitoring, stability testing, custody of chain, and data analytics. L7|ESP is built by scientists for the life sciences community - relentlessly focusing on serving our customers in research, pharma, and diagnostics with the overall goal of better patient outcome. L7 Informatics is supporting customers around the globe that are tackling some of the most challenging and exciting opportunities in healthcare.

Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Agilent customers are finding new ways to treat cancer, ensure food, water, air, and medicine quality and safety, discover new drug treatments, research infectious diseases, and create alternative energy solutions for a greener planet. From start to finish, we have them covered with our vast product solutions and services portfolio. Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Our teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories. Additionally, the unique expertise of Agilent’s CrossLab and technical teams provides valuable insight and support to our customers, helping them fully optimize their laboratories and resources to better focus on what's important: bringing great science to life. In fiscal 2022, Agilent Technologies generated revenue of (US) $6.85 billion.

Corporate Overview Lexicon Pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. Our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. The Genome: Our Source of Discovery We have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. Our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. We have integrated a series of recombinant DNA and chemistry technologies into a systematic drug discovery and development process. Our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. A Diverse Pipeline of Targeted Therapies Our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indications with high unmet medical need. All of our drug candidates are new molecular entities discovered internally by our dedicated drug discovery teams and designed to affect particular points on a genetically-defined pathway that can be used to fight a disease process. We have advanced new therapies across a wide spectrum of human disease, from conditions affecting millions of people, such as diabetes, to carcinoid syndrome, an orphan cancer indication with few treatment options.

Lumos Pharma is a clinical-stage biopharmaceutical company whose mission is to develop new therapies for people with rare diseases, prioritizing its focus where the medical need is high, and the pathophysiology is clear.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.

Develop and market generic and biosimilar drugs. Locations throughout the world.

Nissan Chemical America Corporation is a division of Nissan Chemical Corporation, founded in 1887 as the first chemical fertilizer manufacturer in Japan. A forerunner in chemical innovations for nearly 130 years, Nissan Chemical currently manufactures products for the chemical, agrochemical, and pharmaceutical industries and is a market leader in the production of nanoparticles for the automotive, coatings, electronics, and oil and gas industries.

OM Group, which is divided into two companies OHM PHARMA and OMed, a family based purpose driven company serving the homeopathic community for more than 50 years, providing products, services and education.

QbDVision is the leading Digital CMC Platform for pharmaceutical and biotech manufacturing. Created by industry veterans with decades of drug development experience, we understand the challenges our platform was built to solve. We are preparing our industry to deliver on its promise. We’re creating the modern digital tools our industry needs to realize the full potential of its science. A platform to help organizations swiftly and efficiently deliver the next generation of breakthrough therapies.

Ridgeline Therapeutics is a Houston-based biotech company developing safe and effective drugs that selectively target new mechanisms-of-action to reverse age-related muscle degeneration.

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, a reversible LSD1 inhibitor, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule targeted protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers, initiated by MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com

Scorpius BioManufacturing is a CDMO with integrated solutions for large molecule cGMP manufacturing, process and analytical method development, product characterization, and release testing needs. Scorpius' facility in San Antonio, TX has capacity for both mammalian and microbial clinical manufacturing projects.

At Solugen, we believe planet-scale change starts with the chemistry we use every day. We’re revolutionizing how things are made with the world’s first carbon negative molecule factory: the Bioforge. Harnessing the power of evolved enzymes, plant-based feedstocks, and clean, catalytic reactions, we are making the materials we need to sustain life on Earth—faster, cheaper, and without emissions or waste.

We are a clinical stage oncology focused company developing novel gene therapies focused on dermatological and visceral cancers.

Stingray Therapeutics is working on an exciting new effort to fight cancer with 2nd generation immune-oncology agents. Current efforts in this field are the equivalent of trying to do it with one hand of the immune system tied behind its back. At Stingray, we are unleashing the full immune system to take this fight to an entirely new level. The first generation of immune-oncology therapies, checkpoint inhibitors, leverage adaptive immunity to counter cancer’s immunosuppressive “checkpoints.” However, many patients develop resistance or are non- responsive to treatment given tumors are “cold” (cancer unrecognized by adaptive immune system).

Stramsen Biotech, Inc. is a biopharmaceutical company that uses natural plant based approach to develop medicines that will transform the lives of many patients.

Tvardi Therapeutics is a private, clinical stage biotechnology company developing medicines for diverse cancers and chronic inflammatory and fibrotic diseases. Tvardi is focused on the development of orally delivered, small molecule inhibitors of STAT3, a key signaling molecule positioned at the intersection of many disease pathways.

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body's response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company's lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

Yaso is an early stage drug development company, dedicated to developing a line of drug products for women and men that prevent sexually transmitted disease and unintended pregnancy. We are a team of scientists and business people who have successfully developed, launched and grown women's reproductive health products. We have the worldwide license for a unique polymeric drug with which we are currently developing several dosage forms for preclinical evaluation, leading to our IND.

Mystic Pharmaceuticals developspackaging and dispenser systems for liquid and powder formulations that can be used for delivering drugs, biologics and personal care products.